Gottlieb et al. TYK2i Zasocitinib in PsA. 12 week phase 2 RCT. Skin responses and MDA all favour zasocitinib but maybe not fantastic? PASI75 46%, PASI90 37%, PASI100 26%. MDA in photo. @RheumNow #ACR24 Abstr#1477 https://t.co/iX5iriESV2 https://t.co/RkEmcAZ80x

• Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibit…
• https://x.com/RichardPAConway/status/1858192626425749820/photo/1

Getting more data on using deucravacitinib for PsO/PsA manifestations Impressive effect on scalp psoriasis (which often means a lot to patients) Given how safe it is, it's increasingly tempting to use more of it in mild-mod PsA #ACR24 PSORIATYK SCALP trial ABST1137 @RheumNow https://t.co/vxS3RSlIN0

• https://x.com/drdavidliew/status/1858185727491919901/photo/1

Abst #1473 evaluated association of SJC in PROs from 2 Bimekizumab trials (bDMARD naïve vs TNFi-IR) -bDMARD naïve had less SJC at baseline -In both groups, pts w lower SJC had sustained improvement in pain and fatigue over time. #ACR24 @RheumNow https://t.co/zwxsSbga7c

• https://x.com/AdelaCastro222/status/1858180798488424715/photo/1

Findings from Abstr#1436 reveal that cigarette smoking is not positively associated with radiographic progression in psoriatic arthritis (PsA). Current and past smokers showed a longer time to joint damage progression. This suggests a complex relationship that warrants further… https://t.co/ERsAKoivA4

• https://x.com/i/web/status/1858182057098367025

Are biosimilar multi-switches an issue? real world data: DANBIO 🇩🇰 biosimilar to biosimilar switch having already had a switch prior ('previous ADAo') did not increase cessation The risk of biosimilar switching on immunogenicity is greatly overstated #ACR24 ABST1000 @RheumNow https://t.co/1yAfZrrNd0

• https://x.com/drdavidliew/status/1858180360288526800/photo/1

#1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT ➡️n=290, randomised to PBO, 5/15/30mg gps 💥30mg group 📉 Rapid skin improvement @ Wk 2 ➡️Wk 12 PASI:~2X placebo (-2.5;p=0.004) 🛟Well tolerated ⬆️MDA (28 v. 12.5% p<0.05) promise for other PsA domains #ACR @RheumNow https://t.co/5GusMlVkQ4

• https://x.com/CaoilfhionnMD/status/1858180043656073432/photo/1

Exciting early data for new highly selective TYK2i zasocitinib Improved PASI skin scores (though not as much as IL23i...) Funky skin-related adverse events at higher doses, not sure what to make of that? #ACR24 @rheumnow Abstr#1477 https://t.co/CtOFsoHdBh

• https://x.com/EBRheum/status/1858180043886764484/photo/1
• https://x.com/EBRheum/status/1858180043886764484/photo/1

T2T approaches in early PsA: -STAMP trial (open label, multicenter RCT) eval early SEC (300mg+ MTX15+ 80mg steroid injection) vs SoC (MTX25+80mg steroid injection) -At week 12, 38% pts on SEC vs 17% on SoC achieved ACR50. Also did better on MDA & PASI. -No significant… https://t.co/MflI3d0FqV https://t.co/RjnzeaTyQK

• https://x.com/i/web/status/1858178289262813384
• https://x.com/AdelaCastro222/status/1858178289262813384/photo/1
• https://x.com/AdelaCastro222/status/1858178289262813384/photo/1

#1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai 💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL-17Ai (n=2743) (50%) ⏳ Median time to discontinuation: GUS not reached v 12.3 months for IL-17Ai. 🔴Durable therapy ❓better outcomes #ACR @RheumNow https://t.co/LfA3WygNVq

• https://x.com/CaoilfhionnMD/status/1858177527115608457/photo/1

Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data https://t.co/86J4HWKeIv @RheumNow #ACR24 https://t.co/QYqj5rKHIH

• Bimekizumab in PsA Showed Sustained Reductions in Disease Impact
• https://twitter.com/ericdeinmd/status/1857849021110354277